ESMO 2021 | Potential benefits and challenges of treatment de-escalation strategies

Silke Gillessen, MD, PhD, University of Lugano, Lugano, Switzerland and the Oncology Institute of Southern Switzerland, Bellinzona, Switzerland, discusses the advantages and challenges of treatment de-escalation strategies. Prof. Gillessen explains that specific patient subgroups with prostate cancer could benefit from treatment de-escalation. The Phase III Sakk 96/12 – REDUSE clinical trial (NCT02051218) is currently investigating administration of denosumab every 4 weeks versus every 12 weeks in patients with metastatic prostate cancer. Nevertheless, it is currently very challenging to fund these clinical trials. This interview took place at the European Society for Medical Oncology (ESMO) 2021 congress.